Literature DB >> 7697530

Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis.

M R O'Gorman1, V Corrochano, J Roleck, M Donovan, L M Pachman.   

Abstract

Juvenile dermatomyositis (JDMS) is a vasculopathy affecting primarily skin and muscle. Although the etiology is unknown, immunopathogenetic mechanisms appear to play a role in both the susceptibility to the disease and its progression. We measured the percentage and absolute numbers of B cells and T-cell subsets in the peripheral blood of untreated JDMS patients with active early disease and compared the results with those obtained from a study of peripheral blood obtained from a heatlhy age-related control group. The absolute number of total lymphocytes in the peripheral blood of the JDMS patients was significantly lower (P < 0.002) than that observed in the healthy control population, with an associated decrease in the absolute number of all T-cell subsets. No concomitant decrease in the absolute number of B lymphocytes was observed in the JDMS patients. In contrast, the percentage of B lymphocytes and the T-helper/T-suppressor cell ratio were significantly higher in the JDMS group than in the control group (P < 0.001 and P < 0.002, respectively). Retrospective analysis of JDMS patients' serum samples obtained within 1 month of the flow cytometric evaluation indicated that 79% of the sera contained an antinuclear antibody and 46% had immunoglobulin G values above age-adjusted reference ranges. The increased percentage of B cells, the increased T-helper/T-suppressor cell ratio, the positive antinuclear antibody results, and the increased concentration of serum immunoglobulin suggest that humoral immune dysregulation may contribute to the pathogenesis of JDMS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697530      PMCID: PMC170128          DOI: 10.1128/cdli.2.2.205-208.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  The epidemiology of polymyositis.

Authors:  T A Medsger; W N Dawson; A T Masi
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

3.  Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies.

Authors:  J M Friedman; L M Pachman; M L Maryjowski; R M Radvany; W E Crowe; V Hanson; J E Levinson; C H Spencer
Journal:  Arthritis Rheum       Date:  1983-02

4.  Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis.

Authors:  M L Christensen; L M Pachman; R Schneiderman; D C Patel; J M Friedman
Journal:  Arthritis Rheum       Date:  1986-11

5.  Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups.

Authors:  F W Miller; L A Love; S A Barbieri; J E Balow; P H Plotz
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

6.  Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis.

Authors:  T Ishida; Y Matsumoto; M Ohashi; R Sasaki
Journal:  J Dermatol       Date:  1993-01       Impact factor: 4.005

7.  Autoantibodies in juvenile dermatomyositis.

Authors:  C Montecucco; A Ravelli; R Caporali; S Viola; F De Gennaro; S Albani; A Martini
Journal:  Clin Exp Rheumatol       Date:  1990 Mar-Apr       Impact factor: 4.473

8.  Dermatomyositis, polymyositis, and Coxsackie-B-virus infection.

Authors:  N E Bowles; V Dubowitz; C A Sewry; L C Archard
Journal:  Lancet       Date:  1987-05-02       Impact factor: 79.321

9.  Juvenile dermatomyositis and polymyositis.

Authors:  L M Pachman; M C Maryjowski
Journal:  Clin Rheum Dis       Date:  1984-04

10.  Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens.

Authors:  L M Pachman; J M Friedman; M L Maryjowski-Sweeney; O Jonnason; R M Radvany; G C Sharp; M A Cobb; N D Battles; W E Crowe; C W Fink
Journal:  Arthritis Rheum       Date:  1985-02
View more
  7 in total

1.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

2.  Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

Authors:  M R O'Gorman; L Bianchi; D Zaas; V Corrochano; L M Pachman
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

3.  CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.

Authors:  Michael P Pender
Journal:  Autoimmune Dis       Date:  2012-01-24

4.  Brain-derived neurotrophic factor in patients with Huntington's disease.

Authors:  Chiara Zuccato; Manuela Marullo; Barbara Vitali; Alessia Tarditi; Caterina Mariotti; Marta Valenza; Nayana Lahiri; Edward J Wild; Jenny Sassone; Andrea Ciammola; Anne Catherine Bachoud-Lèvi; Sarah J Tabrizi; Stefano Di Donato; Elena Cattaneo
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

5.  Hyperimmunoglobulin E-recurrent infection syndrome in a patient with juvenile dermatomyositis.

Authors:  J K Min; M L Cho; S C Kim; Y S Lee; S H Lee; S H Park; Y S Hong; C S Cho; H Y Kim
Journal:  Korean J Intern Med       Date:  1999-01       Impact factor: 2.884

Review 6.  Genetics and autoantibodies.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Fulvia Ceccarelli; Guido Valesini; Juan-Manuel Anaya; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 4.505

7.  Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients.

Authors:  Jin-Min Peng; Bin Du; Qian Wang; Li Weng; Xiao-Yun Hu; Chan-Yuan Wu; Yan Shi
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.